Showing results (171-180 of 225) with videos related to

Sort By:
Pageof 23
Nature Genetics|August 16, 2011
The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsivenessJinyi Zhang, Naima Zahir, Qiuhong Jiang, et al.
The Journal of Allergy and Clinical Immunology|October 1, 2025
Asthma remission in the context of other immune-mediated diseasesJosef Smolen, Bruce E Sands, Daniel J Jackson, et al.
RMD Open|August 7, 2026
Ultrasound-based withdrawal of biologics in rheumatoid arthritis (RA-BioStop)Christian Dejaco, Irina Gessl, Rusmir Husic, et al.
ACR Open Rheumatology|March 29, 2022
Predictors of Influenza Vaccination in Early Rheumatoid Arthritis 2017-2021: Results From the Canadian Early Arthritis CohortViviane Ta, Orit Schieir, Marie-France Valois, et al.
Biologicals : Journal of the International Association of Biological Standardization|October 23, 2012
Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012Jonathan Kay, Brian G Feagan, Micheal S Guirguis, et al.
The Journal of Rheumatology|September 17, 2014
A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonistMark C Genovese, Désirée M van der Heijde, Edward C Keystone, et al.
Arthritis and Rheumatism|March 30, 2007
Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritisEsther Jimenez-Boj, Iris Nöbauer-Huhmann, Beatrice Hanslik-Schnabel, et al.
The Journal of Rheumatology|May 17, 2012
Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trialDésirée van der Heijde, Edward C Keystone, Jeffrey R Curtis, et al.
Current Medical Research and Opinion|January 6, 2006
Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) studyAllan Gibofsky, William R Palmer, John A Goldman, et al.
ACR Open Rheumatology|October 28, 2021
A Bridge Too Far? Real-World Practice Patterns of Early Glucocorticoid Use in the Canadian Early Arthritis CohortKathleen M Andersen, Orit Schieir, Marie-France Valois, et al.
Pageof 23